0001683168-26-003012
SEC filingOngoing losses narrowed significantly year-over-year due to gross profit turnaround and operating improvements, despite revenue decline from fewer clinical trial contracts, as liquidity needs and going concern risks intensify amid negative working capital.
Revenue fell 25.0% year-over-year to $11,205, as fewer clinical trial contracts were taken in the third quarter per management's discussion. This decline reflects reduced demand in the core clinical trials segment operated by Alpha Research Institute, exposing the company's reliance on sporadic biotech and CRO engagements alongside ancillary education and CBD channels. While topline remains small-scale, the drop highlights execution risks in a competitive landscape, potentially limiting near-term cash inflows.
Gross profit marked a stark turnaround to $8,160 from a prior-year loss of -$4,465, yielding a 72.8% margin. This swing stems from disciplined cost of revenues relative to topline, transforming a key weakness into a profitability bright spot and contributing to narrower overall losses despite revenue pressure.
Operating income improved 27.8% to -$93,259 from -$129,234, reflecting better absorption of overheads on the positive gross base, though margins stayed deeply negative at -832.3% due to fixed costs outpacing low revenue. Net income followed suit, shrinking 42.7% to -$103,933 from -$181,243, with diluted EPS advancing 55.0% to effectively zero. These gains underscore cost stabilization benefits, even as absolute losses persist.
Cash from operations used -$123,802, an improvement from -$185,315 prior year, aligning with loss narrowing but still signaling ongoing burn. Management emphasizes the need for substantial additional capital to fund operations and repay debts, with no capital expenditure commitments noted.